deamidation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
Retatrutide is a synthetic peptide developed as a single molecule that activates three distinct hormone receptors: GLP-1, GIP, and glucagon. The compound carries the internal designation LY3437943 and was engineered by modifying the backbone of glucose-dependent insulinotropic polypeptide. Its sequence incorporates non-natural amino acids and a fatty acid side chain that extends circulation time. The triple-agonist design aims to combine appetite suppression, improved insulin response, and increased energy expenditure in one agent. Published reports describe it as an investigational product rather than an approved medicine.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Characterising a peptide of this size relies on a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact molecule from related impurities, while electrospray mass spectrometry confirms molecular mass and detects truncation or oxidation products. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates modified residues. Because the molecule carries a lipid chain, assays must also distinguish the correctly conjugated product from incompletely acylated species.
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
==== Intangible Cultural Heritage of Humanity ==== Kimchi-related items have been inscribed on UNESCO's Representative List of the Intangible Cultural Heritage of Humanity by both South and North Korea. This makes kimchi the second intangible heritage that was submitted by two countries, the other one being the folk song "Arirang" which was also submitted by both North and South Korea. "The culture of kimjang" was the subject of the Intangible Cultural Heritage: kimchi is not registered by itself.
== The Strep-tag principle == Just like other short-affinity tags (His-tag, FLAG-tag), the Strep-tag can be easily fused to recombinant proteins during subcloning of its cDNA or gene. For its expression, various vectors for various host organisms (E. coli, yeast, insect, and mammalian cells) are available. A particular benefit of the Strep-tag is its rather small size and the fact that it is biochemically almost inert. Therefore, protein folding or secretion is not influenced and usually it does not interfere with protein function. Strep-tag is especially suited for analysis of functional proteins, because the purification procedure can be kept under physiological conditions. This not only allows the isolation of sensitive proteins in a native state, but it is also possible to purify intact protein complexes, even if just one subunit carries the tag. In the first step of the Strep-tag purification cycle, the cell lysate containing Strep-tag fusion protein is applied to a column with immobilized Strep-Tactin (step 1). After the tagged protein has specifically bound to Strep-Tactin, a short washing step with a physiological buffer (e.g. phosphate buffered saline, PBS) removes all other host proteins (step 2). This is due to Strep-Tactin's low tendency to bind proteins non specifically. Then, the purified Strep-tag fusion protein is gently eluted with a low concentration of desthiobiotin, which specifically competes for the biotin binding pocket (step 3). To regenerate the column, desthiobiotin is removed by application of a HABA containing solution (a yellow azo dye).
=== GDGT-1 – GDGT-4 === GDGT-1, GDGT-2, and GDGT-3 have one, two, and three cyclopentane rings respectively within their isoprenoid biphytane carbon structures, respectively. Nitrososphaerota are the largest producers of these groups in marine and lacustrine environments. Methanogens are not thought to be large synthesizers of these molecules, with the exception of Methanopyrus kandleri, which does produce them. These classes are lower in abundance than GDGT-0 and GDGRT-4. They are used in the TEX86 paleothermometer. GDGT-4 refers to the version with four cyclopentane rings. It is quite abundant (although not easy to differentiate from crenarchaeol on GC/MS, see below). Nitrososphaerota also makes GDGT-4.
He said the deal had been brokered through a partnership with private business and mediated by Secretary of State Marco Rubio and Secretary of Defense Pete Hegseth. Trump claimed that the agreement came "at no cost to the American taxpayer" and would more than double U.S. oil reserves. Few details were disclosed regarding the legal and financial structure of the agreement, including which fields or companies were involved, or how the United States would exercise majority control over the reserves. The Washington Post reported that under the arrangement the United States had gained a controlling stake in nearly a quarter of Venezuela's untapped oil reserves, becoming the majority owner of a newly formed joint venture holding 100-year contracts at the fields, and that a list of 17 oil fields in which the United States would take a stake had circulated before the announcement. According to deal points reviewed by the newspaper, the United States government's stake would be split between equity ownership and guarantees that it would purchase oil produced by the venture at cost to refill the Strategic Petroleum Reserve. Several of the fields lacked infrastructure or access to transport hubs, and those where such infrastructure existed had suffered years of neglect and theft of machinery; the newspaper reported that it was unclear who would make the tens of billions of dollars of investment needed before oil could be pumped, major oil companies having largely regarded such spending as too risky.
==== Wounds healing ==== For abrasions and wounds, nanochemistry has demonstrated applications in improving the healing process. Electrospinning is a polymerization method used biologically in tissue engineering but can also be used for wound dressing and drug delivery. This produces nanofibers that encourage cell proliferation, antibacterial properties, in controlled environment. These properties appear macroscopically, however, nanoscale versions may show improved efficiency due to nanotopographical features. Targeted interfaces between nanofibers and wounds have higher surface area interactions and are advantageous in vivo. There is evidence that certain nanoparticles of silver are useful to inhibit some viruses and bacteria.
Sources: en.wikipedia.org
=== Gelling agents === Gelling agents are food additives used to thicken and stabilize various foods, like jellies, desserts and candies. The agents provide the foods with texture through formation of a gel. Some stabilizers and thickening agents are gelling agents. Typical gelling agents are based on polysaccharides such as natural gums, starches, pectins and agar-agar or proteins such as gelatin. Examples are:
=== Everton === On 20 July 2021, Townsend signed for fellow English club Everton on a two-year contract upon the expiry of his contract with Crystal Palace. Townsend made his debut on 14 August 2021, assisting Richarlison's goal as Everton came from behind to beat Southampton 3–1 on the opening day of the season. On 24 August 2021, Townsend scored the winning goal in an EFL Cup round two fixture against Huddersfield Town. On 13 September 2021, Townsend scored his first Premier League goal for Everton, smashing in a long-range effort from 30 yards to put Everton ahead as they went on to beat Burnley 3–1; this goal won him the Premier League Goal of the Month award. On 20 March 2022, Townsend was forced off the pitch in the 16th minute of an eventual 4–0 loss against former club Crystal Palace in the quarter-finals of the FA Cup, and was later revealed to have suffered an anterior cruciate ligament injury. Subsequently, he went on to miss the remainder of the 2021–22 season as well as the entirety of the 2022–23 season, after which he departed Everton at the conclusion of his contract, having not played in over 18 months.
{\displaystyle {\begin{cases}{\ce {^{244}_{96}Cm ->[{\ce {(\alpha,n)}}] ^{247}_{98}Cf ->[\epsilon][3.11 \ {\ce {h}}] ^{247}_{97}Bk}}\\{\ce {^{244}_{96}Cm ->[{\ce {(\alpha,p)}}] ^{247}_{97}Bk}}\end{cases}}}
== History == Evidence emerged by the end of the 1970s that the newly discovered proton pump (H+/K+ ATPase) in the secretory membrane of the parietal cell was the final step in acid secretion. Literature from anaesthetic screenings led attention to the potential antiviral compound pyridylthioacetamide which after further examination pointed the focus on an anti-secretory compound with unknown mechanisms of action called timoprazole. Timoprazole is a pyridylmethylsulfinyl benzimidazole and appealed due to its simple chemical structure and its surprisingly high level of anti-secretory activity. Optimization of substituted benzimidazoles and their antisecretory effects were studied on the newly discovered proton pump to obtain higher pKa values of the pyridine, thereby facilitating accumulation within the parietal cell and increasing the rate of acid-mediated conversion to the active mediate. As a result of such optimization the first proton pump inhibiting drug, omeprazole, was released on the market. Other PPIs like lansoprazole and pantoprazole would follow in its footsteps, claiming their share of a flourishing market, after their own course of development.
Sources: en.wikipedia.org
As part of decolonization, France established the French Union in 1946 and reorganized Indochina in 1949 as a confederation of associated states within it. In June 1949, they united French Cochinchina with the protectorates of Annam and Tonkin to form the State of Vietnam within the French Union, and installed former Emperor Bảo Đại as head of state. The Chinese Communist victory of 1949 changed the nature of the Indochina War. In 1950, the newly established People's Republic of China and the Soviet Union recognized the DRV while the United States recognized the State of Vietnam. The conflict largely resembled a conventional war between two armies equipped with modern weapons, although guerrilla warfare continued to occur in many areas. The United States provided assistance to France, while China assisted the Viet Minh. French Union forces included colonial troops from the empire – North Africans, Sub-Saharan Africans, Laotian, Cambodian and Vietnamese ethnic minorities – and professional French troops, European volunteers, and units of the Foreign Legion. The use of French metropolitan recruits was forbidden by the government to prevent the war from becoming more unpopular at home. It was called the "dirty war" (la sale guerre) by French leftists. In December 1950, France officially established an army for the State of Vietnam. In September 1951, the US began providing direct economic aid to the State of Vietnam. Segments of the population supported neither the communist Viet Minh nor the French colonialists, and were labeled attentistes.
The three substrates of this enzyme are benzaldehyde, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are benzoic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is benzaldehyde:NAD+ oxidoreductase. Other names in common use include benzaldehyde (NAD+) dehydrogenase, and benzaldehyde dehydrogenase (NAD+). This enzyme participates in benzoate degradation via hydroxylation and toluene and xylene degradation.
=== Values of spin angular momentum === Nuclear spin is an intrinsic angular momentum that is quantized. This means that the magnitude of this angular momentum is quantized (i.e. S can only take on a restricted range of values), and also that the x, y, and z-components of the angular momentum are quantized, being restricted to integer or half-integer multiples of ħ, the reduced Planck constant. The integer or half-integer quantum number associated with the spin component along the z-axis or the applied magnetic field is known as the magnetic quantum number, m, and can take values from +S to −S, in integer steps. Hence for any given nucleus, there are a total of 2S + 1 angular momentum states. The z-component of the angular momentum vector (
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Retatrutide is an investigational peptide that activates the GLP-1, GIP, and glucagon receptors at the same time. It is being studied for obesity and type 2 diabetes and has not been approved for clinical use. The internal code LY3437943 refers to the same molecule.